BCN057 Activates WNT Signaling to Rescue Intestinal Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective solutions for mitigating radiation-induced gastrointestinal syndrome (RIGS) after radiation exposure, particularly in scenarios where immediate administration is not feasible, and existing therapies fail to address the damage to intestinal stem cells leading to severe gastrointestinal symptoms.
Innovation Solution
The compound YEL002/BCN057, a small molecular agent, is administered to activate WNT/β-catenin signaling, promoting intestinal epithelial repair and regeneration by rescuing intestinal stem cells from radiation toxicity, even when administered hours or days post-exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radio-protective drugs are administered prior to radiation exposure, then gastrointestinal injury is ameliorated, but treatment is not feasible when delayed hours or days post-irradiation
Solution Approach 1:
The patent applies preliminary action by pre-activating WNT/β-catenin signaling through administration of YEL002/BCN057 before radiation exposure occurs. This preliminary activation of the protective signaling pathway ensures intestinal stem cell survival and epithelial integrity are maintained at the time of radiation exposure, enabling effective protection even when treatment is initiated before the actual radiation event
Solution Approach 2:
The patent utilizes parameter changes by modifying the temporal window of effective treatment from 'only prior to exposure' to 'up to 24 hours post-exposure'. This is achieved by changing the state of WNT/β-catenin signaling activation timing, allowing the protective mechanism to remain effective during the critical early recovery period after radiation injury
2Reliability
If high doses of radiation are administered for cancer therapy, then tumor control is improved, but intestinal stem cell loss and gastrointestinal toxicity increase
Solution Approach 1:
The patent applies local quality by selectively protecting intestinal stem cells through localized activation of WNT/β-catenin signaling in the intestinal epithelium. YEL002/BCN057 specifically targets and activates this signaling pathway in intestinal crypts, providing localized protection to stem cells while allowing high-dose radiation to continue exerting its tumor-killing effect elsewhere
Solution Approach 2:
The patent uses WNT/β-catenin signaling as an intermediary protective mechanism. The signaling pathway acts as a mediator that translates the presence of YEL002/BCN057 into cellular protection, bridging the gap between radiation exposure and stem cell survival. This intermediary pathway enables stem cells to withstand radiation damage that would otherwise be lethal
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BCN057 significantly improves survival rates and restores intestinal integrity by activating WNT/β-catenin signaling, effectively mitigating RIGS and related symptoms such as mucositis and enteritis, while not providing radio-protection to tumor tissues.
Implementation Method 1
BCN057 has strong WNT activity as demonstrated in TCF/LEF reporter assay. In an ex-vivo crypt organoid model developed from human and mice intestinal epithelium, BCN057 rescued ISCs from radiation toxicity and induced epithelial repair with the activation Wnt/βcatenin signaling.
Data Source
AI summary
The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, oral mucositis, mucositis, and proctitis by the administration of a compound Yel002/BCN057 or an analog thereof.